Results 141 to 150 of about 25,109 (253)
Supplementary Figure 10 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
, 2023 Weining Weng, Tao Meng, Junyi Pu, Linjie Ma, Yi Shen, Zhaohui Wang, Rong Pan, Mingqiao Wang, Caiwei Chen, Lijun Wang, Jianjian Zhang, Biao Zhou, Siyuan Shao, Yu Qian, Shu-Hui Liu, Wenhao Hu, Xun Meng +16 moreopenalex +1 more source281P Silibinin inhibits proliferative and invasive properties of human ovarian carcinoma cells OVCAR8 and SKOV3 through suppression of HRG/HER3 pathway [PDF]
, 2015 Sepehr Javadikooshesh, Majid Momeny, Ghazaleh Zarrinrad, H. Yousefi, Arash Poursheikhani, Pooria Sabouri, Marjan Yaghmaie, Kamran Alimoghaddam, Ardeshir Ghavamzadeh, Javad Tavakkoli-Bazzaz, Seyed H. Ghaffari +10 moreopenalex +1 more sourceSupplementary Figure 8 from An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin
, 2023 Andrew P. Garner, Carl Uli Bialucha, Elizabeth R. Sprague, Joan T. Garrett, Quan Z. Sheng, Sharon Li, Olga Sineshchekova, Parmita Saxena, Cammie R. Sutton, Dongshu Chen, Yan Chen, Huiqin Wang, Jinsheng Liang, Rita Das, Rebecca Mosher, Jian Gu, Alan Huang, Nicole Haubst, Carolin Zehetmeier, Manuela Haberl, Winfried Elis, Christian Künz, Analeah B. Heidt, Kara Herlihy, Joshua Murtie, Alwin G. Schuller, Carlos L. Arteaga, William R. Sellers, Seth A. Ettenberg +28 moreopenalex +1 more sourceSupplementary Figure 1 from HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models
, 2023 Dongsheng Wang, Guoqing Qian, Hongzheng Zhang, Kelly R. Magliocca, Sreenivas Nannapaneni, A.R.M. Ruhul Amin, Michael J. Rossi, Mihir R. Patel, Mark W. El‐Deiry, J. Trad Wadsworth, Zhengjia Chen, Fadlo R. Khuri, Dong M. Shin, Nabil F. Saba, Zhuo G. Chen +14 moreopenalex +1 more sourceA combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC. [PDF]
Cell Oncol (Dordr)Wang Y, Guo H, Han R, Wu Y, He T, Diao M, Xiong A, Zhou F, Cheng L, Zhao C, Li X, Zhou C. +11 moreeuropepmc +1 more sourceSupplementary Figure 1 from 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
, 2023 Dipti Thakkar, Vicente Sancenón, Marvin M. Taguiam, Siyu Guan, Zhihao Wu, Eric Ng, Konrad Paszkiewicz, Piers J. Ingram, Jerome D. Boyd‐Kirkup +8 moreopenalex +1 more source
